Markets · News reference
Filed: 2026-07-24 AccNo: 0001331463-26-000149 Size: 273 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
Keep reading
Nutanix stock surged 9.87% after reporting Q4 2026 results that beat analyst expectations with $757.1 million in revenue (16% YoY growth) and $0.60 diluted EPS versus $0.49 expected. The company also generated strong free cash flow of $277.6 million and provided optimistic fiscal 2027 guidance of $3.18-$3.23 billion in revenue and $850-$950 million in free cash flow.
Read original at the-motley-foolSummit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-researchLululemon has demonstrated a strong track record of beating earnings estimates, with an average surprise of 3.22% over the last two quarters. The company has a positive Earnings ESP of +0.70% combined with a Zacks Rank #3 (Hold), suggesting a high probability of another earnings beat in its September 3, 2026 report. Stocks with this combination historically beat consensus estimates nearly 70% of the time.
Read original at zacks-investment-researchTMC The Metals Company has gained 32% recently after narrowing losses in Q2, but faces significant challenges. With zero revenue, a dwindling cash pile lasting only 4-5 quarters, and no regulatory approval for seafloor mining, the company's future hinges on obtaining a U.S. commercial recovery permit expected by late 2027. While global demand for critical metals supports long-term potential, substantial regulatory and international opposition risks remain.
Read original at the-motley-foolHormel Foods reported Q3 adjusted EPS of 37 cents, beating consensus estimates, but net sales fell 2.4% to $2.96B, missing expectations. The company expanded operating margins by 60 basis points despite volume declines across segments. Hormel lowered fiscal 2026 sales guidance to $12.1-$12.2B but raised EPS guidance to $1.45-$1.51, reflecting a Brazil divestiture and challenging external environment.
Read original at zacks-investment-researchBath & Body Works (BBWI) exceeded Q2 earnings and sales expectations with adjusted EPS of 62 cents (vs. 24 cents consensus) and net sales of $1,514 million. The company returned to direct sales growth for the first time since 2021, benefiting from improved digital conversion and expanded distribution. BBWI raised its FY'26 adjusted EPS guidance to $2.60-$2.80 and free cash flow to $650 million, driving shares up 7.5%.
Read original at zacks-investment-research